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Summary
Systemic therapy of head and neck carcinoma is reserved for locally advanced and metastatic disease. Concomitant 
use of cisplatin and irradiation is still standard protocol for treatment of locally advanced disease although immunoradio-
therapy with cetuximab seems to be a good alternative with similar results. The best option for fi rst-line treatment of 
 advanced or metastatic disease is polychemotherapy with addition of cetuximab in patients in good clinical condition. 
Limited options are available for second-line therapy mostly due to poor performance status of the patients. HPV-positive 
tumors make a special subgroup of HNSCC in which targeted therapy plays the most important role.
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SUSTAVNO LIJEČENJE KARCINOMA GLAVE I VRATA
Sažetak
Sustavno liječenje karcinoma glave i vrata je rezervirano za lokalno uznapredovalu i metastatsku bolest. Konkomi-
tantna primjena cisplatine uz zračenje još uvijek predstavlja standard liječenja za lokalno uznapredovalu bolest, iako imu-
noradioterapija s cetuximabom predstavlja dobru alternativu sa sličnim rezultatima. Najbolja opcija za liječenje uznapredo-
vale ili metastatske bolesti je polikemoterapija uz dodatak cetuximaba za sve bolesnike u dobrom kliničkom stanju. Moguć-
nosti druge linije liječenja su vrlo ograničene, najviše zbog lošeg općeg stanja bolesnika. HPV-pozitivni tumori predstavljaju 
posebnu podgrupu karcinoma pločastih stanica glave i vrata u kojima najvažniju ulogu igra liječenje ciljanom terapijom.
KLJUČNE RIJEČI: karcinom pločastih stanica, glava i vrat, cisplatina, cetuximab, radioterapija, humani papilomavirus
Carcinoma of the head and neck represents a 
heterogeneous group of tumours which include 
tumours originating from lip, oral cavity, hypo-
pharynx, oropharynx, nasopharynx and larynx. 
Majority of these tumours (around 90%) belong to 
squamous cell carcinoma group.
Throughout the history, tobacco and alcohol 
were considered as the main cause of this disease. 
In the past decade, new break-through was made 
in understanding head and neck squamous cell 
carcinoma (HNSCC) pathogenesis when infection 
with high-risk HPV (Human papillomavirus) and 
especially with HPV type 16 (HPV16) has been 
implicated as a cause of a growing subset of HN-
SCCs, mainly those arising from the oropharynx 
(1). Distinction of this subgroup of tumours is of 
great importance whereas these tumours express 
diff erent biology and clinical behaviour with more 
favourable prognosis which might require less in-
tensive therapy.
Early disease (stages I and II) are treated by 
conservative surgery or radiotherapy with the 
similar outcome.
Locally advanced HNSCC includes stage III 
or IV A and B carcinomas that invade proximate 
structures or spread to cervical lymph nodes, 
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whereas recurrent/metastatic (R/M) HNSCC in-
volves tumours that present with locoregional re-
currence or distant metastases.
Patients with locally advanced disease (stage 
III and IV) are treated by surgery including recon-
struction followed by postoperative radiotherapy. 
High-risk patients (nodal extracapsular extension 
and/or R1 resection) are candidates for postopera-
tive chemoradiotherapy with cisplatin as single 
agent chemotherapy. This is based on Bernier et 
al. study results published in 2004. Study com-
pared two groups of patients treated for locally 
advanced head and neck cancer, one with postop-
erative irradiation plus concomitant chemothera-
py (100 mg/m2 of body-surface area on days 1, 22, 
and 43 of the radiotherapy regimen) and one with 
postoperative irradiation alone. The study results 
showed that addition of chemotherapy to radio-
therapy prolongs progression free survival (47% 
vs. 36%), overall survival (53% vs 40%) and reduc-
es the rate of disease reccurences (18% vs 31%)(2).
Patients who are not candidates for surgery 
because of nonresectability or the expected out-
come of surgery would be mutilization, can be 
treated by primary chemoradiotherapy.
Historical standard of primary chemoradio-
therapy for the locally advanced disease is high 
dose cisplatin applied concomitantly with radio-
therapy. Several studies have shown that concomi-
tant use of cetuximab with radiotherapy in com-
parison with radiotherapy alone, demonstrated 
higher response rate, longer disease-free progres-
sion and longer overall survival and therefore was 
included in treatment guidelines. 5-year overall 
survival reported in Bonner et al. study published 
in Lancet in 2010. Was 45.6 % in the cetuximab-
plus-radiotherapy group and 36.4% in the radio-
therapy-alone group (3). There was no head-to-
head study comparing cisplatin based chemoradio-
therapy and cetuximab based immunoradiotherapy 
so decision between these two options should be 
made by the oncologist. Cetuximab is less toxic and 
as there is no clear evidence of effi  cacy of cisplatin 
based chemoradiotherapy in elderly, it could prob-
ably be used in elderly and patients with poor per-
formance status.
Several ongoing randomized phase III trials 
are investigating use of sequential chemoradio-
therapy (chemotherapy protocols based on cispla-
tin and 5-FU with or without the addition of a tax-
ane). According to the published results, appli-
cation of induction chemotherapy showed no 
signifi cant survival improvement with signifi cant 
toxicity (neutropenia, febrile neutropenia, muco-
sitis, nausea and vomiting) when radiation plus 
high dose three-week cisplatin was used in further 
course of treatment (4,5). Recommended treat-
ment after induction includes radiotherapy alone 
or chemoradiotherapy with weekly cisplatin, car-
boplatin or cetuximab with no signifi cant diff er-
ence in treatment eff ectiveness (6,7,8). A French 
investigative group made an individual-patient 
meta-analysis of chemotherapy in non-metastatic 
nasopharyngeal carcinoma (MAC-NPC) that in-
cluded 19 trials and 4,806 patients which suggest-
ed that adding induction chemotherapy or adju-
vant chemotherapy to chemoradiotherapy im-
proved the outcome in terms of tumor control 
probability and survival compared with chemora-
diotherapy alone (9).
Recommended fi rst-line treatment in R/M 
HNSCC is combination platinum/fl uorouracil 
with or without cetuximab for fi t patients (10). The 
epidermal growth factor receptor (EGFR) is over-
expressed in up to 90% of cases of HNSCC and its 
overexpression correlates with poor clinical out-
comes (11,12). Cetuximab is a monoclonal anti-
body against the extracellular domain of EGFR 
and it is the only targeted agent currently ap-
proved for HNSCC. Addition of cetuximab to 
polychemotherapy (cisplatin at a dose of 100 mg/
m2 of body-surface area on day 1 or carboplatin 
AUC5 as a 1-hour intravenous infusion on day 1 
plus fl uorouracil at a dose of 1000 mg/m2/day for 4 
days every 3 weeks) in the fi rst-line treatment of 
recurrent or metastatic head and neck cancer, was 
shown to improve OS (10,1 vs. 7,4 months), PFS 
(5,6 vs. 3,3 months), and response rates (36% vrs 
20%) in EXTREME study. Based on results of this 
trial, the drug was included in ESMO and NCCN 
guidelines for treatment of R/M HNSCC (13). In 
patients, whose polychemotherapy tolerability is 
anticipated to be poor, monochemotherapy should 
be treatment of choice. Drugs that should be con-
sidered in single-agent protocols include metho-
trexate, docetaxel, 5-FU, cetuximab and platinum-
based drug, all with similar results (response rates 
15-35%) (14). Limited options are available for 
second-line therapy mostly because small propor-
tion of patients are fi t enough to be suitable candi-
dates for second-line therapy. Standard treatment 
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of patients with incurable metastatic or locally ad-
vanced disease should be directed by patient’s 
performance status. Phase II trial was conducted 
with afatinib (oral irreversible ErbB family block-
er) which showed similar clinical activity to cetux-
imab (15). Based on these results, the phase III 
LUX Head and Neck 1 clinical trial presented at 
the 2014 ESMO meeting assessed the effi  cacy of 
afatinib as monotherapy compared with single-
agent methotrexate as second-line treatment in 
HNSCC (16). The study showed increase in PFS of 
0.9 months, improvement in tumour shrinkage 
and response rate in afatinib group, whereas no 
improvement in OS was noted. Given results are 
unlikely to lead to drug approval but studies 
 evaluating adjuvant afatinib in locally advanced 
HNSCC after chemoradiotherapy are ongoing 
(LUX Head and Neck 2) and they will hopefully 
clarify the role of afatinib in HNSCC.
It is especially important to emphasize the 
role of immunotherapy in the context of treatment 
of HPV-positive HNSCC. Lyford-Pike et al. dem-
onstrated that the PD-1/PD-L1 (programmed cell 
death ligand) pathway is involved in immune re-
sistance of HPV-associated HNSCC (17). PD-L1 
binds to the PD-1 receptor and activates the PD-1 
checkpoint pathway, which blocks the immune 
response by downregulating T-cell eff ector func-
tions and subsequently facilitates HPV infection 
and development of HPV associated lesions (18). 
PD-1 antibodies which inhibit the interaction be-
tween PD-1 and PD-L1 are being evaluated in clin-
ical trials in a variety of cancers. Pembrolizumab 
and nivolumab have been allready approved for 
the treatment of metastatic malignant melanoma 
(19,20). The clinical response to anti-PD-1 antibod-
ies has correlated with PD-L1 expression and with 
the presence of tumour-infi ltrating lymphocytes 
in several tumours, including HNSCC (21). Some 
novel anti-PD-L1 antibodies are also being evalu-
ated in clinical trials in HNSCC (for example anti 
PD-1 antibodies nivolumab, pidilizumab and lam-
brolizumab and PD-L1 targeted agents atezoli-
zumab and durvalumab mostly in phase I and II 
clinical trials). Eff orts are made to develop thera-
peutic vaccines that will induce a cellular T-cell 
immune response to recognize and eliminate 
HPV-infected cells (22). Combining the vaccine 
with chemotherapy and immunotherapy will 
hopefully increase the activity of vaccine and help 
with bett er disease control. Preclinical data sug-
gest that HPV vaccination could act as an immune-
stimulating agent, resulting in the improvement 
of response rates to an anti-PD-1 checkpoint in-
hibitor (23). These strategies are expected to be 
studied in further clinical trials.
It is also important to mention the eff orts that 
are made in fi eld of personalized cancer therapy. 
In four recent studies, based on whole-exone se-
quencing of altogether 190 HNSCC specimens, in-
vestigators identifi ed key mutations of several tu-
mour suppression genes, such as TP53 (60%), CD-
KN2A (9% to 74%), PI3KCA (8% to 20%), Notch 
(9% to 19%) and PTEN (13.6%)(24,-27). These stud-
ies revealed, for the fi rst time, the presence of nov-
el inactivating mutations in tumour suppressor 
genes that regulate cellular squamous diff erentia-
tion within the normal stratifi ed squamous epi-
thelium, such as NOTCH1, TP63, and FBXW7, as 
driver genetic events of neoplastic transformation 
in the head and neck area. MOSCATO 01 trial in-
cluded 78 heavily pretreated patients with HN-
SCC whose biopsy specimens, obtained from the 
primary or metastatic tumour sites, were subject-
ed to comparative genomic hybridization and 
next-generation sequencing for up to 74 target 
genes (28). Results were reviewed to identify ac-
tionable molecular aberrations for which targeted 
therapy may be available through clinical trials or 
approved drugs. Following pathways were ob-
served: fi broblast growth factors (FGFs) and their 
receptors (FGFRs; 35%), phosphoinositide 3-ki-
nase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) (26%), MYC (24%), CDKs/Cyclins (13%), 
EGFR (9%), HER2 (7%), Notch (4%), and KIT (2%). 
Altogether 10 patients were treated with a target-
ed therapy on the basis of the genomic profi le. 
Three of them att ained partial response, three had 
stable disease, one developed disease progression, 
and two were not evaluable. This study shows 
early results of a personalized medicine strategy 
in R/M HNSCC, and further results will be await-
ed with great interest.
Despite all the innovations in therapy and 
bett er understanding of pathogenesis, there is still 
no signifi cant improvement in survival rates and 
prognosis of patients with advanced head and 
neck cancer. First positive results were observed 
with the use of biological treatment and we have 
high ationsfrom future research with this type of 
therapy. It is also important to emphasize the need 
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for prevention strategies which would identify 
high-risk population and work on early detection 
of the disease.
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